126 related articles for article (PubMed ID: 17425296)
1. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
2. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
3. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
4. Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.
Dinges J; Akritopoulou-Zanze I; Arnold LD; Barlozzari T; Bousquet PF; Cunha GA; Ericsson AM; Iwasaki N; Michaelides MR; Ogawa N; Phelan KM; Rafferty P; Sowin TJ; Stewart KD; Tokuyama R; Xia Z; Zhang HQ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4371-5. PubMed ID: 16750628
[TBL] [Abstract][Full Text] [Related]
5. 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Diaz G; Glaser KB; Guo J; Harris CM; Li J; Marcotte PA; Moskey MD; Oie T; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR
J Med Chem; 2008 Mar; 51(5):1231-41. PubMed ID: 18260617
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
7. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
8. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
Ho CY; Ludovici DW; Maharoof US; Mei J; Sechler JL; Tuman RW; Strobel ED; Andraka L; Yen HK; Leo G; Li J; Almond H; Lu H; DeVine A; Tominovich RM; Baker J; Emanuel S; Gruninger RH; Middleton SA; Johnson DL; Galemmo RA
J Med Chem; 2005 Dec; 48(26):8163-73. PubMed ID: 16366598
[TBL] [Abstract][Full Text] [Related]
9. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
Shultz MD; Cao X; Chen CH; Cho YS; Davis NR; Eckman J; Fan J; Fekete A; Firestone B; Flynn J; Green J; Growney JD; Holmqvist M; Hsu M; Jansson D; Jiang L; Kwon P; Liu G; Lombardo F; Lu Q; Majumdar D; Meta C; Perez L; Pu M; Ramsey T; Remiszewski S; Skolnik S; Traebert M; Urban L; Uttamsingh V; Wang P; Whitebread S; Whitehead L; Yan-Neale Y; Yao YM; Zhou L; Atadja P
J Med Chem; 2011 Jul; 54(13):4752-72. PubMed ID: 21650221
[TBL] [Abstract][Full Text] [Related]
11. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
Bilodeau MT; Balitza AE; Koester TJ; Manley PJ; Rodman LD; Buser-Doepner C; Coll KE; Fernandes C; Gibbs JB; Heimbrook DC; Huckle WR; Kohl N; Lynch JJ; Mao X; McFall RC; McLoughlin D; Miller-Stein CM; Rickert KW; Sepp-Lorenzino L; Shipman JM; Subramanian R; Thomas KA; Wong BK; Yu S; Hartman GD
J Med Chem; 2004 Dec; 47(25):6363-72. PubMed ID: 15566305
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
13. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
14. 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
Dinges J; Ashworth KL; Akritopoulou-Zanze I; Arnold LD; Baumeister SA; Bousquet PF; Cunha GA; Davidsen SK; Djuric SW; Gracias VJ; Michaelides MR; Rafferty P; Sowin TJ; Stewart KD; Xia Z; Zhang HQ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4266-71. PubMed ID: 16759855
[TBL] [Abstract][Full Text] [Related]
15. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
18. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
[TBL] [Abstract][Full Text] [Related]
19. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
[TBL] [Abstract][Full Text] [Related]
20. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
